179 related articles for article (PubMed ID: 30072388)
1. Alternate Endpoints for Phase II Trials in Advanced Neuroendocrine Tumors.
Imaoka H; Sasaki M; Takahashi H; Hashimoto Y; Ohno I; Mitsunaga S; Watanabe K; Umemoto K; Kimura G; Suzuki Y; Kan M; Ikeda M
Oncologist; 2019 Jan; 24(1):47-53. PubMed ID: 30072388
[TBL] [Abstract][Full Text] [Related]
2. Progression-free survival as a surrogate endpoint in advanced neuroendocrine neoplasms.
Imaoka H; Sasaki M; Takahashi H; Hashimoto Y; Ohno I; Mitsunaga S; Watanabe K; Umemoto K; Kimura G; Suzuki Y; Ikeda M
Endocr Relat Cancer; 2017 Sep; 24(9):475-483. PubMed ID: 28684542
[TBL] [Abstract][Full Text] [Related]
3. Validation of Progression-Free Survival Rate at 6 Months and Objective Response for Estimating Overall Survival in Immune Checkpoint Inhibitor Trials: A Systematic Review and Meta-analysis.
Kok PS; Cho D; Yoon WH; Ritchie G; Marschner I; Lord S; Friedlander M; Simes J; Lee CK
JAMA Netw Open; 2020 Sep; 3(9):e2011809. PubMed ID: 32897371
[TBL] [Abstract][Full Text] [Related]
4. Everolimus, lutetium-177 DOTATATE and sunitinib for advanced, unresectable or metastatic neuroendocrine tumours with disease progression: a systematic review and cost-effectiveness analysis.
Mujica-Mota R; Varley-Campbell J; Tikhonova I; Cooper C; Griffin E; Haasova M; Peters J; Lucherini S; Talens-Bou J; Long L; Sherriff D; Napier M; Ramage J; Hoyle M
Health Technol Assess; 2018 Sep; 22(49):1-326. PubMed ID: 30209002
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and safety of sunitinib in Japanese patients with progressive, advanced/metastatic, well-differentiated, unresectable pancreatic neuroendocrine tumors: final analyses from a Phase II study.
Ito T; Tori M; Hashigaki S; Kimura N; Sato K; Ohki E; Sawaki A; Okusaka T
Jpn J Clin Oncol; 2019 Apr; 49(4):354-360. PubMed ID: 30834940
[TBL] [Abstract][Full Text] [Related]
6. Association Between Tumor Progression Endpoints and Overall Survival in Patients with Advanced Neuroendocrine Tumors.
Ter-Minassian M; Zhang S; Brooks NV; Brais LK; Chan JA; Christiani DC; Lin X; Gabriel S; Dinet J; Kulke MH
Oncologist; 2017 Feb; 22(2):165-172. PubMed ID: 28179574
[TBL] [Abstract][Full Text] [Related]
7. Assessment of Correlation Between Early and Late Efficacy Endpoints to Identify Potential Surrogacy Relationships in Non-Hodgkin Lymphoma: a Literature-Based Meta-analysis of 108 Phase II and Phase III Studies.
Zhu R; Lu D; Chu YW; Chai A; Green M; Zhang N; Jin JY
AAPS J; 2017 May; 19(3):669-681. PubMed ID: 28224402
[TBL] [Abstract][Full Text] [Related]
8. Validating ORR and PFS as surrogate endpoints in phase II and III clinical trials for NSCLC patients: difference exists in the strength of surrogacy in various trial settings.
Hua T; Gao Y; Zhang R; Wei Y; Chen F
BMC Cancer; 2022 Sep; 22(1):1022. PubMed ID: 36171546
[TBL] [Abstract][Full Text] [Related]
9. Value of Tumor Growth Rate (TGR) as an Early Biomarker Predictor of Patients' Outcome in Neuroendocrine Tumors (NET)-The GREPONET Study.
Lamarca A; Crona J; Ronot M; Opalinska M; Lopez Lopez C; Pezzutti D; Najran P; Carvhalo L; Franca Bezerra RO; Borg P; Vietti Violi N; Vidal Trueba H; de Mestier L; Schaefer N; Sundin A; Costa F; Pavel M; Dromain C;
Oncologist; 2019 Nov; 24(11):e1082-e1090. PubMed ID: 30910869
[TBL] [Abstract][Full Text] [Related]
10. Comparative effectiveness of combined therapy inhibiting EGFR and VEGF pathways in patients with advanced non-small-cell lung cancer: a meta-analysis of 16 phase II/III randomized trials.
Zhao Y; Wang H; Shi Y; Cai S; Wu T; Yan G; Cheng S; Cui K; Xi Y; Qi X; Zhang J; Ma W
Oncotarget; 2017 Jan; 8(4):7014-7024. PubMed ID: 27690345
[TBL] [Abstract][Full Text] [Related]
11. Bevacizumab plus capecitabine in patients with progressive advanced well-differentiated neuroendocrine tumors of the gastro-intestinal (GI-NETs) tract (BETTER trial)--a phase II non-randomised trial.
Mitry E; Walter T; Baudin E; Kurtz JE; Ruszniewski P; Dominguez-Tinajero S; Bengrine-Lefevre L; Cadiot G; Dromain C; Farace F; Rougier P; Ducreux M
Eur J Cancer; 2014 Dec; 50(18):3107-15. PubMed ID: 25454413
[TBL] [Abstract][Full Text] [Related]
12. The impact of high PD-L1 expression on the surrogate endpoints and clinical outcomes of anti-PD-1/PD-L1 antibodies in non-small cell lung cancer.
Ito K; Miura S; Sakaguchi T; Murotani K; Horita N; Akamatsu H; Uemura K; Morita S; Yamamoto N
Lung Cancer; 2019 Feb; 128():113-119. PubMed ID: 30642442
[TBL] [Abstract][Full Text] [Related]
13. Surrogate Endpoints as Predictors of Overall Survival in Metastatic Urothelial Cancer: A Trial-level Analysis.
Ghali F; Zhao Y; Patel D; Jewell T; Yu EY; Grivas P; Montgomery RB; Gore JL; Etzioni RB; Wright JL
Eur Urol Open Sci; 2023 Jan; 47():58-64. PubMed ID: 36601043
[TBL] [Abstract][Full Text] [Related]
14. Progression-Free Survival Early Assessment Is a Robust Surrogate Endpoint of Overall Survival in Immunotherapy Trials of Hepatocellular Carcinoma.
Cabibbo G; Celsa C; Enea M; Battaglia S; Rizzo GEM; Busacca A; Matranga D; Attanasio M; Reig M; Craxì A; Cammà C
Cancers (Basel); 2020 Dec; 13(1):. PubMed ID: 33396833
[TBL] [Abstract][Full Text] [Related]
15. Optimized Image-Based Surrogate Endpoints in Targeted Therapies for Glioblastoma: A Systematic Review and Meta-Analysis of Phase III Randomized Controlled Trials.
Suh CH; Kim HS; Jung SC; Choi CG; Kim SJ; Kim KW
Korean J Radiol; 2020 Apr; 21(4):471-482. PubMed ID: 32193895
[TBL] [Abstract][Full Text] [Related]
16. Relationship between response rates and median progression-free survival in non-Hodgkin's lymphoma: A meta-analysis of published clinical trials.
Mangal N; Salem AH; Li M; Menon R; Freise KJ
Hematol Oncol; 2018 Feb; 36(1):37-43. PubMed ID: 28707346
[TBL] [Abstract][Full Text] [Related]
17. Do Surrogate Endpoints Better Correlate with Overall Survival in Studies That Did Not Allow for Crossover or Reported Balanced Postprogression Treatments? An Application in Advanced Non-Small Cell Lung Cancer.
Hashim M; Pfeiffer BM; Bartsch R; Postma M; Heeg B
Value Health; 2018 Jan; 21(1):9-17. PubMed ID: 29304946
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and Safety of Everolimus in Extrapancreatic Neuroendocrine Tumor: A Comprehensive Review of Literature.
Faggiano A; Malandrino P; Modica R; Agrimi D; Aversano M; Bassi V; Giordano EA; Guarnotta V; Logoluso FA; Messina E; Nicastro V; Nuzzo V; Sciaraffia M; Colao A
Oncologist; 2016 Jul; 21(7):875-86. PubMed ID: 27053503
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and Safety of Sunitinib in Patients with Well-Differentiated Pancreatic Neuroendocrine Tumours.
Raymond E; Kulke MH; Qin S; Yu X; Schenker M; Cubillo A; Lou W; Tomasek J; Thiis-Evensen E; Xu JM; Croitoru AE; Khasraw M; Sedlackova E; Borbath I; Ruff P; Oberstein PE; Ito T; Jia L; Hammel P; Shen L; Shrikhande SV; Shen Y; Sufliarsky J; Khan GN; Morizane C; Galdy S; Khosravan R; Fernandez KC; Rosbrook B; Fazio N
Neuroendocrinology; 2018; 107(3):237-245. PubMed ID: 29991024
[TBL] [Abstract][Full Text] [Related]
20. Determination of an optimal response cut-off able to predict progression-free survival in patients with well-differentiated advanced pancreatic neuroendocrine tumours treated with sunitinib: an alternative to the current RECIST-defined response.
Lamarca A; Barriuso J; Kulke M; Borbath I; Lenz HJ; Raoul JL; Meropol NJ; Lombard-Bohas C; Posey J; Faivre S; Raymond E; Valle JW
Br J Cancer; 2018 Jan; 118(2):181-188. PubMed ID: 29161241
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
